ArticleFrontiers in pharmacology2026
Liuwei Dihuang pills attenuates cognitive dysfunction in
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) features progressive cognitive decline, Aβ aggregation, neurofibrillary tangles, mitochondrial dysfunction and central insulin resistance, lacking effective disease-modifying treatments. Liuwei Dihuang Pills (LWDHP) exert neuroprotective effects, while its dual regulatory mechanisms targeting mitochondrial homeostasis and cerebral IRS/AKT/GSK3β insulin signaling remain unclear. Methods: Results: LWDHP significantly rescued spatial learning and memory deficits, reduced cerebral Aβ plaques and tau hyperphosphorylation. LWDHP balanced mitochondrial fusion-fission via upregulating PGC-1α/MFN2 and downregulating FIS1, elevated synaptic structural proteins (MAP2, PSD-95, SYN), restored cerebral insulin sensitivity by elevating InsR, normalizing IRS-1/AKT/GSK3β phosphorylation, and suppressing tau hyperphosphorylation. Discussion: LWDHP alleviates AD cognitive impairment through dual regulation of mitochondrial homeostasis and IRS/AKT/GSK3β insulin signaling, providing solid preclinical evidence for its anti-AD application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.